Loading company…
Reistone Biopharma develops medicines for immuno-inflammatory disorders.
Reistone Biopharma develops drug candidates for immuno-inflammatory diseases, including a JAK1 inhibitor in Phase III trials and candidates targeting BTK and RORgt. The company is based in Shanghai, China, and raised approximately USD 100 million in Series A funding in May 2022 from Huagai Capital, Hanne Capital, Yinglian Health Industry Fund, Zero2IPO Ventures and Zhangjiang Haoheng Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Reistone Biopharma Company Limited? This is my company